PLAINSBORO, N.J., Aug 20, 2010 (GlobeNewswire via COMTEX) — Integra LifeSciences Holdings Corporation(IART 35.76, -0.57, -1.57%) announced today the opening of its state-of-the art Center for Research, Education and Training in Irvine, California. The new facility is designed to accommodate hands-on simulated surgical training, while also creating a laboratory setting for research and development for Integra’s products in spine, orthopedics and neurosurgery.
Integra will host its first spine research lab in the Center on August 21, 2010. Spine surgeons from throughout the United States, along with Integra Spine’s product development staff, will be participating.
The Center features 2,800 square feet of combined classroom training and lab space, and includes four fully equipped surgical stations, designed to mirror an operating room, which will allow surgeons to practice procedures on cadaveric specimens and test new product concepts. It also includes instruments for use in orthopedic procedures, c-arm fluoroscopy systems, and endoscopy towers for video imaging. The lecture room is hardwired for internet access and is equipped with audio/visual equipment.
“Integra understands the needs of the surgeon,” said Brian Larkin, Integra’s President, Global Spine & Orthobiologics and Head of Strategic Development. “As medical devices and surgical techniques are constantly evolving, advanced hands-on training and surgeon involvement in device development is critical for improving patient care. We’re pleased that we can offer this opportunity in our new state-of-the art facility.”
Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is a global medical device company dedicated to improving the quality of life for millions of patients every year. The company’s products are used primarily in orthopedics, neurosurgery and general surgery. Headquartered in Plainsboro, New Jersey, Integra has research and manufacturing facilities throughout the world. Please visitwww.integralife.com for more information.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use and effectiveness of the Center. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use our products or attend the Center may affect the prospects for the use of our products in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading “Risk Factors” included in Item IA of Integra’s Annual Report on Form 10-K for the year ended December 31, 2009 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. The forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
IART – G
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Integra LifeSciences Holdings Corp.